Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o
Target Price
The average target price of 2172.HK is 12.9 and suggests 59.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i